Biomea Fusion (BMEA)

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

The Biomea Fusion, Inc. Common Stock (BMEA) stock price today is $1.51, reflecting a +1.00% move since the market opened. The company’s market capitalization stands at $109.17M, with a daily trading volume of $1.18M shares. For investors tracking price trends, Biomea Fusion, Inc. Common Stock stock has ranged between $1.40 and $1.54 today. The previous closing price was $1.50.

Ready to get started? Follow the steps below, or read our guide on how to buy Biomea Fusion stock on Kraken starting from $10.